| Literature DB >> 27334782 |
Chang Ching Yeh1, Hsiao Yun Tai2, Hong Chou2, Keh Gong Wu3, Horng Der Shen4.
Abstract
PURPOSE: Fusarium species are among prevalent airborne fungi and causative agents of human respiratory atopic disorders. We previously identified a 36.5-kDa F. proliferatum component recognized by IgE antibodies in 9 (53%) of the 17 F. proliferatum-sensitized atopic serum samples. The purpose of this study is to characterize the 36.5-kDa allergen of F. proliferatum.Entities:
Keywords: F. proliferatum; IgE cross-reactivity; allergen; vacuolar serine protease
Year: 2016 PMID: 27334782 PMCID: PMC4921698 DOI: 10.4168/aair.2016.8.5.438
Source DB: PubMed Journal: Allergy Asthma Immunol Res ISSN: 2092-7355 Impact factor: 5.764
Primers used in cDNA cloning, expression and site-directed mutagenesis of the vacuolar serine protease of Fusarium proliferatum
| Name | Nucleotide sequence in 5' to 3'-end orientation |
|---|---|
| VSP-F-1 | 5'-25AA(G/A)A(A/G)(C/T)GC(T/C)CC(T/C/A)TGGGG41-3' |
| VSP-R-1 | 5'-761CC(A/G)GC(A/G)AT(A/G)TG(A/G/T)GG(A/G)(A/G/T)A(A/C/G)GCCAT739-3' |
| FuVSP-GSP1 | 5'-186GGCAGGCCCTCGAAGTCGACGT164-3' (For 5' race) |
| FuVSP-GSP2 | 5'-661ATCTTCGCTCCCGGTCTGAACATT684-3' (For 3' race) |
| AP | 5'-GGCCACGCGTCGACTAGTACT-(dT)16-3' |
| AUAP | 5'-GGCCACGCGTCGACTAGTAC-3' |
| AAP | 5'-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGIIG-3' |
| FuVSP-5' Sma I | 5'-TCCCCCGGGG10GACGGCGAGACCGAGCGACAGGC32-3' |
| FuVSP-3' Hind III | 5'-CCCAAGCTTTTA969GTAGCTACCAGCCTCAACAATCTTCTT943-3' |
| FVSP K88A-f | 5'-256GGTACTGTCGCCGGTGCGAAGTACGGTGTTGC287-3' |
| FVSP K88A-r | 5'-287GCAACACCGTACTTCGCACCGGCGACAGTACC256-3' |
Fig. 1(A) The nucleotide and deduced amino acid sequences of the vacuolar serine protease protein of F. proliferatum (Fus p 9.0101, GenBank accession no. KJ462778). Numbers to the right indicate the positions of the nucleotides and the deduced amino acid residues of the sequences. The amino acid triad (D45, H77 and S243) which is characteristic of serine proteases is depicted in bold type and shaded. Three potential N-glycosylation sites are in bold letters and underlined. The vertical arrow marks the proposed amino terminus of the mature vacuolar serine protease. The stop codon TAA is denoted with an asterisk. Nucleotides in gray correspond to those synthesized and used as primers for PCR in the cDNA cloning of the vacuolar serine protease of F. proliferatum as shown in Table. The sequences corresponding to primers FuVSP-5'Sma I and FuVSP-3'Hind III used in the preparation of recombinant mature Fusarium vacuolar serine protease protein and its K88A mutant (FVSP K88A-f and FVSP K88A-r) are boxed. (B) Composite alignment of the deduced amino acid sequences of the proposed mature Fus p 9.0101, Pen ch 18, Pen o 18 and the Pen ch 13 fungal serine protease allergens. Dashes denote spaces introduced to optimize the alignment. Identical amino acid residues are denoted with asterisks.
Fig. 2Antigenicity of the wild-type and mutant fungal vacuolar serine protease allergens. (A) Coomassie blue-stained protein profiles of the recombinant wild-type Fus p 9.0101 and Pen ch 18 allergens as well as the Fus p 9.0101K88A and Pen ch 18 K89A mutants on PVDF membranes. (B) Immunoblot reactivities to MoAb FUM20. (C) Immunoblot reactivities to IgE antibodies in 9 sera from asthmatic patients (strip nos. 1-9) and 1 serum from 1 house dust mite-sensitized asthmatic patient (strip no. 10).
Fig. 3Immunoblot inhibition of IgE- (panel B) and MoAb FUM20- (panel C) binding to nFus p 9.0101 in crude F. proliferatum extracts with purified rFus p 9.0101 and BSA as inhibitors. (A) Coomassie blue-stained protein profile of F. proliferatum extracts and protein molecular weight markers. (B) IgE binding to the 36.5-kDa component using serum no. 1 from Fig. 2C (lane 1); this binding activity was inhibited dose-dependently by 20 µg (lane 2) and 5 µg (lane 3) of rFus p 9.0101, but not 20 µg of BSA (lane 4). (C) MoAb FUM20 binding to the 36.5-kDa component of F. proliferatum extracts (lane 1); this binding activity was inhibited by 20 µg (lane 2) of rFus p 9.0101, but not 20 µg of BSA (lane 3).
Fig. 4Inhibition of IgE-immunoblot reactivity to Fus p 9.0101. IgE-immunoblot experiment was carried out with serum no. 9 from Fig. 2C (lane 9). Serum was pre-absorbed with 10 µg of the wild-type Fus p 9.0101, the wild-type Pen ch 18, the Fus p 9.0101K88A mutant, the Pen ch 18 K89A mutant, or BSA as indicated.